NeoPharm Investigators to Present New and Updated Clinical Data on Cintredekin Besudotox at the American Association of Neurological Surgeons Annual Meeting

NeoPharm, Inc. (NASDAQ/NM:NEOL):
Who/What: NeoPharm, Inc. (NASDAQ/NM:NEOL) clinical data
presentations on cintredekin besudotox ("IL13-PE38QQR")

Where: American Association of Neurological Surgeons (AANS) 2006
Annual Meeting
April 22-27, 2006
Moscone Convention Center
San Francisco, CA

When: Monday, April 24, 2006
Scientific Session I - Tumor
3:15pm - 3:30pm
Long-Term Follow-Up of Convection Enhanced Delivery of
Cintredekin Besudotox (IL13-PE38QQR): UCSF Experience from
Phase I Study.

Authors: Sandeep Kunwar, MD; Michael Prados, MD;
Susan Chang, MD; Eric Burton, MD; Andy T.
Parsa, MD, PhD; Michael McDermott, MD;
David Croteau, MD; Mitchel S. Berger, MD

Discussant: Edward H. Oldfield, MD

Tuesday, April 25, 2006
AANS/CNS Section on Tumors I
4:00pm - 4:15pm
Results of a Phase I Study: Convection-Enhanced Delivery
of Cintredekin Besudotox (IL13-PE38QQR) Followed by
Radiation Therapy without and with Temozolmide in Newly
Diagnosed Malignant Glioma Patient"

Authors: Michael A. Vogelbaum, MD, PhD; John H.
Sampson, MD, PhD; Sandeep Kunwar, MD;
Susan Chang, MD; Frederick F. Lang, MD;
Mark E. Shaffrey, MD; Anthony L. Asher, MD;
David Croteau, MD; Kristen Parker, BS;
Christine Lauay, PhDL; Jeffrey W. Sherman,
MD, FACP; Raj K. Puri, MD, PhD


Wednesday, April 26, 2006
Poster Session - Tumor
2:00pm - 2:45pm
Validation of a Patient-Specific Convection-Enhanced
Delivery Simulation Algorithm with SPECT Imaging

Authors: John H. Sampson, MD; Raghu Raghavan; Martin
L. Brady; James Provenzale; Denise
Lally-Goss; Lisa Tansey; Sharon McGehee;
Hidenobu Ochial; Deborah Smith; Neal Petry;
David Croteau, MD; Amy Grahn; Jeffrey
Sherman, MD, FACP; Raj Puri, MD, PhD;
Allan H. Friedman; Kim Greer; R.R. Edward
Coleman; Terence Wong; Darrell D. Bigner;
Ira Pastan; Christoph Pedain.

NeoPharm's Commitment to Oncology

NeoPharm employees share a common goal: bringing hope to cancerpatients and their families through the research and development ofnew cancer drugs and therapies. The Company's oncology portfolio isbuilt on two novel, proprietary platforms: a tumor-targeting platform,and the NeoLipid(R) Liposomal Drug Delivery platform. Through itsresearch and clinical studies, as well as its work with physicians,scientists, and advocacy groups, NeoPharm is helping to enhance thelives of cancer patients.

About NeoPharm, Inc.

NeoPharm, Inc., based in Waukegan, Illinois, is a publicly tradedbiopharmaceutical company dedicated to the research, development andcommercialization of new and innovative cancer drugs for therapeuticapplications. The Company has a portfolio of cancer compounds invarious stages of development. Additional information can be obtainedby visiting NeoPharm's Website at www.neopharm.com.

Forward Looking Statements - This press release contains"forward-looking statements" within the meaning of Section 27A of theSecurities Act of 1933 and Section 21E of the Securities Exchange Actof 1934. The Company has tried to identify such forward-lookingstatements by use of such words as "expects," "intends," "hopes,""anticipates," "believes," "could," "may," "evidences" and"estimates," and other similar expressions, but these words are notthe exclusive means of identifying such statements. Such statementsinvolve risks and uncertainties, including, but not limited to, thoserisks and uncertainties relating to difficulties or delays infinancing, development, testing, obtaining regulatory approval,production and marketing of the Company's drug and non-drug compounds,including, but not limited to, cintredekin besudotox (IL13-PE38QQR),uncertainty regarding the availability of third party productioncapacity, unexpected adverse side effects or inadequate therapeuticefficacy of the Company's drug and non-drug compounds, including, butnot limited to, cintredekin besudotox (IL13-PE38QQR), that could slowor prevent products coming to market, uncertainty regarding theCompany's ability to market its drug and non-drug products ,including,but not limited to, cintredekin besudotox (IL13-PE38QQR), theuncertainty of patent protection for the Company's intellectualproperty or trade secrets associated with the Company's drug andnon-drug compounds, including, but not limited to, those surroundingcintredekin besudotox (IL13-PE38QQR), and other risks detailed fromtime to time in filings the Company makes with the Securities andExchange Commission including its annual reports on Form 10-K andquarterly reports on Forms 10-Q. Such statements are based onmanagement's current expectations, but actual results may differmaterially due to various factors, including those risks anduncertainties mentioned or referred to in this press release.Accordingly, you should not rely on these forward-looking statementsas a prediction of actual future results.